Healthcare / Medical DevicesTokyo
$1075.00
-23.00 (-2.09%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $247.0M · quality 53.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8.7B
P/E
13.3x
↓EV/EBITDA
2.7x
↓ROE
4.4%
↑Gross Margin
44.0%
↓Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.4%
FCF CAGR
-16.4%
FCF margin
0.5%
FCF / Net income
0.09x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $13.62B · net income $713.7M · FCF $67.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $13.62B | $13.62B | $13.03B | $12.59B | $12.33B |
| Net Income | $713.7M | $713.7M | $840.9M | $154.0M | $482.2M |
| EBITDA | $1.64B | $1.64B | $1.73B | $1.50B | $1.47B |
| EPS | 80.75 | 80.75 | 95.41 | 16.92 | 53.00 |
| Gross Margin | 44.0% | 44.0% | 43.8% | 43.5% | 43.8% |
| Operating Margin | 7.4% | 7.4% | 5.3% | 6.4% | 6.0% |
| Net Margin | 5.2% | 5.2% | 6.5% | 1.2% | 3.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
| Current Ratio | 8.00 | 8.00 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $67.7M | $67.7M | $1.77B | $247.0M | $116.0M |
| Returns | |||||
| ROE | 4.4% | 4.4% | 5.3% | 1.0% | 3.3% |
| Valuation | |||||
| P/E | 13.32 | 13.32 | 9.58 | 52.96 | 16.51 |
| EV/EBITDA | 2.70 | 2.70 | 1.46 | 3.04 | 3.02 |
| P/B | 0.58 | 0.58 | 0.51 | 0.55 | 0.54 |
| Growth & Yield | |||||
| Revenue Growth | 4.5% | 4.5% | 3.5% | 2.1% | — |
| EPS Growth | -15.4% | -15.4% | 463.9% | -68.1% | — |
| Dividend Yield | 4.3% | 4.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
5.7%
EPS terminal req.
$95.39
Spread vs growth
-21.1%
5Y implied EPS CAGR
7.4%
EPS terminal req.
$115.42
Spread vs growth
-22.8%
10Y implied EPS CAGR
8.7%
EPS terminal req.
$185.88
Spread vs growth
-24.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+17.2%
Start / end P/E
10.0x → 13.3x
EPS bridge
95.41 → 80.75
Residual
-5.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.